KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial.

Michael H Gold, Lisa Donofrio, Sachin Shridharani, Amir Moradi, Brian Biesman, Melissa Chiang, Rosalyn George, Kristel Polder, Nowell Solish, Rob Schwarcz, Anna-Karin Berg, Felipe Weinberg, Eva Axén

Aesthet Surg J 45(8) 828-835

PMID40242960
PMCIDPMC12260373
DOI10.1093/asj/sjaf063
发表日期2025-04-17
入排依据:未发现恶性肿瘤人群证据。
已检查 6 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 1 张未列出。
摘要

摘要

BACKGROUND: RelabotulinumtoxinA (relaBoNT-A; Relfydess, Galderma, Uppsala, Sweden) is a novel, ready-to-use liquid form of botulinum toxin A, created using PEARL technology to produce a highly effective, complex-free formulation. OBJECTIVES: This study reports the patient-assessed effectiveness and satisfaction outcomes from the relaBoNT-A Phase 3 READY-1 study. METHODS: Adults with moderate-to-severe glabellar lines were randomized 3:1 to receive relaBoNT-A (50 U) or placebo in a 6-month, double-blind, multicenter study. Patient-reported endpoints at maximum frown included ≥1 grade improvement on the glabellar line subject live assessment (GL-SLA) scale from baseline and Global Aesthetic Improvement Scale (GAIS) score. Satisfaction and well-being investigations used the Facial Lines Treatment Satisfaction Questionnaire (FLTSQ), Natural Expressions Questionnaire, and FACE-Q Psychological Function Questionnaire. RESULTS: Overall, 233 adults received relaBoNT-A and 74 received placebo. RelaBoNT-A responder rates for ≥1-grade GL-SLA improvement from baseline at Day 7 and Months 1, 3, and 6 were 97.2%, 97.7%, 90.0%, and 71.0%, respectively, vs 18.9%, 26.8%, 27.5%, and 22.4% with placebo (P < .001). GAIS responder rates were 74.3% to 98.1% (relaBoNT-A) and 9.0% to 16.2% (placebo). Posttreatment FLTSQ Rasch-transformed scores were higher with relaBoNT-A (≥62.5) than placebo (≤49.8) for the Appearance Module and Treatment Satisfaction Module (relaBoNT-A: ≥83.0; placebo: ≤36.8). RelaBoNT-A-treated patients reported looking natural (≥83.3%) and feeling confident when making facial expressions (≥75.7%). Mean change in FACE-Q well-being score was higher with relaBoNT-A (11.0-13.7) vs placebo (0.6-4.5). CONCLUSIONS: Adults with moderate-to-severe glabellar lines receiving a single relaBoNT-A treatment reported significant improvements in glabellar line severity throughout the 6-month study period. RelaBoNT-A provided natural looking results, high satisfaction, and psychological well-being improvements.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Patient-reported responder rate on the GL-SLA static 4-point categorical scale over the 6-month study period (ITT population). A responder was defined as a patient achieving ≥1 grade improvement from baseline in glabellar line severity score on the GL-SLA scale at maximum frown. P value for the between-group difference at each study visit: P < .001. Posttreatment study visits and assessments were conducted on Day 7, Day 14, and Months 1 to 6. D, day; GL-SLA, glabellar lines subject live assessment; ITT, intention to treat; RelaBoNT-A, relabotulinumtoxinA.
非 KM Figure
Figure 2Figure 2. Patient-reported GAIS responder rate at maximum frown during the 6-month study period (ITT population). A responder was defined as a patient who responded as “improved,” “much improved,” or “very much improved” on the patient GAIS at maximum frown. Posttreatment study visits and assessments were conducted on Day 7, Day 14, and Months 1 to 6. GAIS, Global Aesthetic Improvement Scale; ITT, intention to treat; RelaBoNT-A, relabotulinumtoxinA.
非 KM Figure
Figure 3Figure 3. Patient-reported FLTSQ score for the Appearance Module and Treatment Satisfaction Module at maximum frown during the 6-month study period (ITT population). The FLTSQ was used to assess treatment outcome from the patient's perspective. The sum of each patient's FLTSQ scores was converted to a Rasch-transformed total score, with a higher total score indicating greater patient satisfaction. Posttreatment, study visits, and assessments were conducted on Day 7, Day 14, and Months 1 to 6. FLTSQ, Facial Lines Treatment Satisfaction Questionnaire; ITT, intention to treat; RelaBoNT-A, relabotulinumtoxinA.
非 KM Figure
Figure 4Figure 4. Patient-reported data at Months 1 and 6 after treatment from (A) the FLTSQ (B) the Natural Expressions Questionnaire at Months 1 and 6 after treatment (ITT population). FLTSQ, Facial Lines Treatment Satisfaction Questionnaire; ITT, intention to treat; RelaBoNT-A, relabotulinumtoxinA.
非 KM Figure
Figure 5Figure 5. Mean change from baseline in Rasch-transformed score for FACE-Q psychological well-being at Months 1, 3, and 6 after treatment (ITT population). FACE-Q scores were converted to a Rasch-transformed total score, with a higher total score indicating greater patient satisfaction. The mean change from baseline is reported at Months 1, 3, and 6. ITT, intention to treat; RelaBoNT-A, relabotulinumtoxinA.
非 KM Figure
Figure 6Figure 6. Treatment results in 2 patients injected with relaBoNT-A 50 U in the GLs. Photographs were taken before treatment on Day 0 (A, D), at 1 month (B, E), and 6 months (C, F) after treatment. GAIS was assessed by the patients themselves at maximum frown. (A-C) A 57-year-old woman with severe GLs at maximum frown at baseline (GL-ILA). GAIS results much improved at Months 1 and 6. Very satisfied with treatment at Months 1 and 6. (D-F) A 35-year-old woman with severe GLs at maximum frown at baseline (GL-ILA), GAIS results at Month 1: very much improved; Month 6: much improved; satisfied with treatment at Months 1 and 6.
非 KM Figure